Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07517263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Trial sites reduced: 655 → 646 locations
    • Eligibility criteria expanded, about 6 words
  2. Trial sites expanded: 643 → 655 locationsv7
  3. Trial sites expanded: 635 → 643 locationsv6
  4. Trial sites expanded: 618 → 635 locationsv5
  5. Trial sites expanded: 559 → 618 locationsv4
  6. Trial sites expanded: 492 → 559 locationsv3
  7. Trial sites expanded: 72 → 492 locations
    • Start date: Apr 13, 2026 to May 11, 2026
    v2
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.
Trial Details
NCT Number NCT07517263
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Cardiovascular Disease and Lipoprotein(a)
Related terms Cardiovascular Diseases, Myocardial Infarction, Stroke
Enrollment 5,700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov